NRSNW

NASD NeuroSense Therapeutics Ltd. - Warrant
Nov 10, 2026 · 6:40 PM ET LAST TRADE Market Closed

$0.0056 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0056, and at the day’s high of $0.0056

YTD change
-98.35%
vs 20-day SMA
-64.02%
vs 200-day SMA
N/A

Price ranges

Previous day
$0.0075 $0.0076
open $0.0076 close $0.0075
-$0.0001 (-1.32%)
Today
$0.0055 $0.0056
open $0.0055 now $0.0056
+$0.0001 (+1.82%)
Past week
$0.0053 $0.0140
from $0.0075 now $0.0056
-$0.0019 (-25.33%)
Past month
$0.0011 $0.0900
from $0.0900 now $0.0056
-$0.0844 (-93.78%)
This year
$0.0011 $0.4015
from $0.3400 now $0.0056
-$0.3344 (-98.35%)

Price & Performance

-0.09 (-92.54%) / 6M

$-0.0103$0.0652$0.1408$0.2163May 11Aug 18Nov 9

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 99.5% away from all-time highs of $1.0600
  • NRSNW is down 98% since the beginning of the year
  • NRSNW is down 98% over the past 12 months
  • NRSNW is down 94% over the past 1 month

NRSNW reads poor: the 12-month move is -97.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable N/A
EPS N/A
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A

Balance sheet & scale

IncomeN/A
RevenueN/A
CashN/A
DebtN/A
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap N/A

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $919.96 +1.73%
IQV IQVIA Holdings Inc $278.84 +2.58%
CRL Charles River Laboratories International, Inc. $353.34 +4.69%
ICLR ICON Plc $207.59 +1.39%
IT Gartner, Inc. $191.02 +0.48%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.